Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18594050 | 0.92 | MAPT (0.36) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL19863092 | 0.92 | MAPT (0.38) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL19863056 | 0.90 | MAPT (0.33) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL19866430 | 0.90 | PRKDC (0.30) | — | |
| SCHEMBL19863057 | 0.89 | MAPT (0.36) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL19863032 | 0.88 | MAPT (0.34) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL18594137 | 0.88 | MAPT (0.35) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL18594053 | 0.88 | MAPT (0.37) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL19863036 | 0.87 | ALOX5 (0.33) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL19863079 | 0.87 | MAPT (0.36) | MAPTALDH1A1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10230056-B2 | Heterocyclic compound and organic light emitting element comprising same | LG CHEM, LTD. (KR) | 2019-03-12 | — | — | US | disclosed |
| US-20180047914-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10230056-B2 | Heterocyclic compound and organic light emitting element comprising same | CRY1, CRY2, NR2E3 | MAPT 746/4885ALDH1A1 242/4885MEN1 798/4885 |
| US-20180047914-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | CRY1, CRY2, NR2E3 | MAPT 746/4885ALDH1A1 242/4885MEN1 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.